Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Vor Biopharma Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
06/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform"
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
04/14/2023 8-K Quarterly results
12/14/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/07/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Vor Biopharma Inc. and Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein",
"Opinion of Cooley LLP",
"Securities Purchase Agreement, by and between Vor Biopharma Inc. and RA Capital Healthcare Fund, L.P",
"Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million"
12/07/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel and Tolerated Mylotarg TM",
"Company Presentation"
11/29/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/17/2022 8-K Quarterly results
04/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/17/2021 8-K Quarterly results
02/09/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 9, 2021 Vor Biopharma Inc. Delaware 001-39979 81-1591163 100 Cambridgepark Drive Suite 400 Cambridge, Massachusetts 02140 655-6580 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant ...",
"Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant",
"Investor Contact:"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy